专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012018767A2 ANTIBODIES DIRECTED AGAINST IL-17 审中-公开
标题翻译：针对IL-17的抗体
公开(公告)号：WO2012018767A2
公开(公告)日：2012-02-09
申请号：PCT/US2011046201
申请日：2011-08-02
申请人： ANAPTYSBIO INC , HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
发明人： HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92
摘要： The invention relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The invention also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.
摘要翻译：本发明涉及分离的IL-17结合剂，其包含包含SEQ ID NO：1的免疫球蛋白重链多肽和任选的包含SEQ ID NO：23的免疫球蛋白轻链多肽，不同之处在于SEQ ID NO：1的一个或多个特异性残基 NO：1和SEQ ID NO：23被不同的残基取代。本发明还提供了使用IL-17结合剂治疗IL-17介导的疾病的载体，组合物和方法。

2. 发明申请

WO2014172448A3 ANTIBODIES DIRECTED AGAINST ACTIVIN RECEPTOR TYPE II (ACTRII) 审中-公开
标题翻译：针对II型活化受体的抗体（ACTRII）
公开(公告)号：WO2014172448A3
公开(公告)日：2015-01-08
申请号：PCT/US2014034344
申请日：2014-04-16
申请人： ANAPTYSBIO INC
发明人： VERDINO PETRA , BOWERS PETER , KING DAVID
IPC分类号： A61K39/395 , C12N15/00
CPC分类号： C07K16/2863 , C07K2317/76
摘要： The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to an activin receptor type II (ActRII) protein (e.g., either or both of ActRIIA and/or ActRIIB). The invention provides an ActRII-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the ActRII-binding agent to treat an ActRII-mediated disease.
摘要翻译：本发明涉及分离的免疫球蛋白重链多肽和分离的免疫球蛋白轻链多肽，其结合活化素受体II型（ActRII）蛋白（例如ActRIIA和/或ActRIIB中的任一者或两者）。本发明提供了包含上述免疫球蛋白重链多肽和免疫球蛋白轻链多肽的ActRII结合剂。本发明还提供使用ActRII-结合剂治疗ActRII介导的疾病的相关载体，组合物和方法。

3. 发明公开

EP2547781A4 METHOD OF PRODUCING TRANSCRIPTS USING CRYPTIC SPLICE SITES 审中-公开
标题翻译：的生产方法使用隐藏TRANSCRIPTS剪接进入的地方
公开(公告)号：EP2547781A4
公开(公告)日：2014-04-23
申请号：EP11756860
申请日：2011-03-15
申请人： ANAPTYSBIO INC
发明人： HORLICK ROBERT , MACOMBER JOHN , CUBITT ANDREW , KING DAVID
IPC分类号： C12P19/34 , C07H21/02 , C07K16/00 , C07K16/24 , C12N15/11 , C12N15/63 , C12P21/02
CPC分类号： C12P21/02 , C07K16/00 , C07K16/244 , C07K2317/34 , C12N15/111 , C12N15/63 , C12N2310/14 , C12N2330/00

4. 发明专利

BR112013002831A2 anticorpos direcionados contra a il-17 未知
公开(公告)号：BR112013002831A2
公开(公告)日：2016-11-01
申请号：BR112013002831
申请日：2011-08-02
申请人： ANAPTYSBIO INC
发明人： WU BETTY , KING DAVID , DALTON JENNIFER , ALTOBELL LAURENCE III , BOWERS PETER , HORLICK ROBERT A , ROBERTS TRACI , ZHANG XUE
IPC分类号： A61K39/395 , C07K16/00 , C12N5/16 , C12N15/00 , C12P21/06
摘要： anticorpos direcionados contra a il-17. a invenção refere-se a um agente de il-17-ligante isolado que compreende uma cadeia polipéptida pesada de imunoglobulina compreendendo a seq id no: 1 e, opcionalmente, uma cadeia polipéptida leve de imunoglobulina compreendendo a seq id no: 23, exceto que um ou mais resíduos específico da seq id no: 1 e seq id no: 23 são substituídos por um resíduo diferente. a invenção também proporciona vetores, composições e métodos para a utilização do agente de il-17-ligante para o tratamento de uma doença de il-mediada.

5. 发明专利

SG11201909395TA ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF 未知
公开(公告)号：SG11201909395TA
公开(公告)日：2019-11-28
申请号：SG11201909395T
申请日：2018-04-27
申请人： TESARO INC , ANAPTYSBIO INC
发明人： JUN HELEN , KEHRY MARILYN , BOWERS PETER , KING DAVID , BOBILEV DMITRI , GHOSH SRIMOYEE , HUANG BAOCHUAN , JENKINS DAVID
IPC分类号： A61K39/00 , C07K16/28 , A61P35/00
摘要： APCOR TUMOR CELL APC OR TUMOR CELL REINVIGORATED T CELL CYTOKINES EFFECTOR MECHANISMS INHIBITORY aTIM- ACTIVATION SIGNAL SIGNAL PD-1 LAG-3 TCR )ritAG-3 aPD-1 EXHAUSTED T CELL ACTIVATION SIGNAL TCR Ag MHC TIM-3 Ag MHC (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT omit VIII °nolo Holollm olo lionoiliflo oimIE (10) International Publication Number WO 2018/201096 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/030027 (22) International Filing Date: 27 April 2018 (27.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,221 27 April 2017 (27.04.2017) US 62/578,215 27 October 2017 (27.10.2017) US 62/614,998 08 January 2018 (08.01.2018) US 62/625,276 01 February 2018 (01.02.2018) US 62/657,384 13 April 2018 (13.04.2018) US (71) Applicants: TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). ANAP- TYSBIO, INC. [US/US]; 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). (72) Inventors: JUN, Helen, Toni; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). KEHRY, Marilyn; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). BOWERS, Peter; c/o Anaptysbio, Inc., 10421 Pa- cific Center Court, Suite 200, San Diego, CA 92121 (US). KING, David, J.; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). BOBILEV, Dmitri; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). GHOSH, Srimoyee; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). HUANG, Baochuan; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). JENKINS, David; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). (74) Agent: ESPINO, Christine, G. et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (54) Title: ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THERE- OF FIGURE 1 1-1 01 O O 1-1 (57) : The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided 0 are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is \" responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease. C [Continued on next page] WO 2018/201096 Al MIDEDIMOMOIDEIRDERI00101011M0101101EIMOVOIMIE (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))

6. 发明专利

AU2011285922B2 Antibodies directed against IL-17 未知
公开(公告)号：AU2011285922B2
公开(公告)日：2016-06-16
申请号：AU2011285922
申请日：2011-08-02
申请人： ANAPTYSBIO INC
发明人： HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
IPC分类号： C07K16/00 , A61K39/395 , C12N5/16 , C12N15/00 , C12P21/06
摘要： The disclosure relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The disclosure also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.

7. 发明专利

ES2633145T3 Anticuerpos dirigidos contra IL-17 未知
公开(公告)号：ES2633145T3
公开(公告)日：2017-09-19
申请号：ES11815158
申请日：2011-08-02
申请人： ANAPTYSBIO INC
发明人： HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
IPC分类号： C07K16/00 , A61K39/395 , C12N5/16 , C12N15/00 , C12P21/06
摘要： Un agente de unión a IL-17 aislado que comprende ambos de los siguientes: (a) un polipéptido de cadena pesada de inmunoglobulina que comprende la SEQ ID NO: 78 y (b) un polipéptido de cadena ligera de inmunoglobulina que comprende la SEQ ID NO: 24.

8. 发明公开

EP2601217A4 ANTIBODIES DIRECTED AGAINST IL-17 有权
标题翻译：抗体与人IL-17
公开(公告)号：EP2601217A4
公开(公告)日：2014-03-05
申请号：EP11815158
申请日：2011-08-02
申请人： ANAPTYSBIO INC
发明人： HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
IPC分类号： C07K16/00 , A61K39/395 , C12N5/16 , C12N15/00 , C12P21/06
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92

9. 发明专利

SG10201913677SA ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF 未知
公开(公告)号：SG10201913677SA
公开(公告)日：2020-03-30
申请号：SG10201913677S
申请日：2018-04-27
申请人： TESARO INC , ANAPTYSBIO INC
发明人： JUN HELEN , KEHRY MARILYN , BOWERS PETER , KING DAVID , BOBILEV DMITRI , GHOSH SRIMOYEE , HUANG BAOCHUAN , JENKINS DAVID
摘要： The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease.

10. 发明专利

NZ607615A Antibodies directed against il-17 未知
公开(公告)号：NZ607615A
公开(公告)日：2015-03-27
申请号：NZ60761511
申请日：2011-08-02
申请人： ANAPTYSBIO INC
发明人： HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
IPC分类号： C07K16/00 , A61K39/395 , C12N5/16 , C12N15/00 , C12P21/06
摘要： Disclosed is an isolated IL-17-binding agent comprising both of the following: (a) an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 78, and (b) an immunoglobulin light chain polypeptide comprising SEQ ID NO: 24. >24 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIKR >78 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNHWMNWVRQTPGKGLEWVAAINEDGSEKYYVGSVKVRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARDYYDILTRDYYDILTDYYIHYWYFDLWGRGTLVTVSS

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式